
Avutometinib/Abemaciclib/Fulvestrant Combo Is Active, Safe in CDK4/6 Inhibitor–Resistant HR+/HER2– Metastatic Breast ...
The combination of avutometinib (VS-6766), abemaciclib (Verzenio), and fulvestrant (Faslodex) demonstrated a manageable safety profile and preliminary efficacy in patients with hormone receptor (HR)–positive, HER2-negative metastatic breast cancer (HR+…